1. In Vivo
  2. >>Archive

J&J Closes the Loop with Animas Acquisition

Johnson & Johnson, whose LifeScan Inc. division is number one in the $6 billion glucose monitoring industry, acquired Animas, which after Medtronic MiniMed, is the number two player in the insulin pump market. J&J gets not only a leading insulin pump business, but also technology that lends itself to the future goals of all diabetes companies; the development of an artificial pancreas, or at least, the ability to automatically deliver insulin in response to automated continuous blood glucose measurements.

Johnson & Johnson , whose LifeScan Inc. division is number one in the $6 billion glucose monitoring industry, acquired Animas Corp. , which after Medtronic Inc. 's Medtronic MiniMed , is the number two player in the insulin pump market. [See Deal] Animas, a public company since 2004, [See Deal] will become a standalone entity reporting through LifeScan, and president Katherine Crothall, PhD will remain president of the division.

Under the terms of the transaction, which was approved by the boards of directors of both companies, J&J is paying...

More from Archive

More from In Vivo

BioBytes: AI-Related Deals In Q2 ‘25

 
• By David Wild

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By Jo Shorthouse

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.